Cargando…
SGLT2 Inhibition in HFpEF. Do We Need More Quantitative and Load Independent Metrics to Understand the Results of the EMPEROR-Preserved Trial?
Autores principales: | Korosoglou, Grigorios, Giusca, Sorin, Kelle, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795365/ https://www.ncbi.nlm.nih.gov/pubmed/35097034 http://dx.doi.org/10.3389/fcvm.2021.822968 |
Ejemplares similares
-
Similarities and Differences Between HFmrEF and HFpEF
por: Li, Peixin, et al.
Publicado: (2021) -
Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
por: Mangner, Norman, et al.
Publicado: (2023) -
Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF)
por: Valero-Muñoz, María, et al.
Publicado: (2022) -
Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022) -
Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
por: Martínez-Sellés, Manuel, et al.
Publicado: (2022)